NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
TGTX
TG Therapeutics, Inc.
TGTX has the edge over NVO overall, supported by stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TGTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
TGTX's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over TGTX in the historical PE scenario, which offers more potential upside but is not a forecast.
TGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $7.91 | -88% |
| Forward | 26x | $64.56 | — |
| Fair | 39x | $25.80 | -60% |
| Current | 98x | $64.56 | — |
| Expensive | 148x | $97.38 | +51% |
Historical ranges are pointers, not guarantees.
TGTX's PE is in its expensive range at 98x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its fair range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TGTX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TGTX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TGTX on earnings, with more consistent year-over-year improvement.
TGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.52 | +282% |
| Q3 2026 | $0.66 | -76% |
| Q2 2026 | $2.74 | +621% |
| Q1 2026 | $2.86 | +1044% |
| Q4 2025 | $2.77 | +1747% |
| Q3 2025 | $2.79 | +$2.89 |
| Q2 2025 | $0.38 | -38% |
| Q1 2025 | $0.25 | +8.7% |
| Q4 2024 | $0.15 | +650% |
TGTX earned $0.66 per share over the past year, down 76% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TGTX on profitability, with a higher operating margin.
TGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.9M | +61% |
| Q2 2026 | $240.3M | +70% |
| Q1 2026 | $204.9M | +70% |
| Q4 2025 | $192.6M | +78% |
| Q3 2025 | $161.7M | +93% |
| Q2 2025 | $141.1M | +92% |
| Q1 2025 | $120.9M | +90% |
| Q4 2024 | $108.2M | +146% |
TGTX has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +15 points |
| Q2 2026 | 9% | -16 points |
| Q1 2026 | 17% | +9.9 points |
| Q4 2025 | 26% | -1.5 points |
| Q3 2025 | 18% | +3.3 points |
| Q2 2025 | 25% | +13 points |
| Q1 2025 | 7.1% | +22 points |
| Q4 2024 | 28% | +56 points |
TGTX's operating margin was 33% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
TGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44.9M | +$68.2M |
| Q2 2026 | $39M | +427% |
| Q1 2026 | -$17.9M | +$10.8M |
| Q4 2025 | $19.6M | +$45.3M |
| Q2 2025 | $7.4M | +34% |
| Q1 2025 | -$28.7M | -$20.5M |
| Q4 2024 | -$25.7M | -$12.5M |
| Q4 2023 | -$13.2M | +$10.7M |
TGTX has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.4M shares |
| 1 year | -3.2% | -5.1M shares |
| 3 years | 0% | +53.3K shares |
| 5 years | +18% | +23.6M shares |
| Available history | +76% | +67.6M shares |
TGTX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100M |
| Q2 2026 | — |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $78.2M |
| Q2 2025 | $6.9M |
| Q1 2025 | $6.1M |
| Q4 2024 | $6.6M |
TGTX spent $200M buying back its own shares over the past year, up 104% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over TGTX on leverage, with a lower net debt burden relative to earnings.
TGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.5x | Healthy |
TGTX's net debt is about 1.6 years of its operating earnings (EBITDA), about the same as a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 86.3 | Overbought |
TGTX's weekly RSI is 69 (neutral) and its Stochastic is 86 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over TGTX on valuation relative to its sector.
TGTX PE vs Healthcare Sector
| Metric | TGTX | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 75 | 29 | 46 pts above |
TGTX is trading at 98x earnings, a 278% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.6 | 12% above |
| 20 week MA | $55.4 | 17% above |
| 50 week MA | $43.0 | 50% above |
| 100 week MA | $38.7 | 67% above |
| 200 week MA | $28.6 | 126% above |
TGTX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $53.3 | +390% |
| 2021 | $53.3 | $19.4 | -64% |
| 2022 | $19.4 | $8.12 | -58% |
| 2023 | $8.12 | $17.1 | +110% |
| 2024 | $17.1 | $32.5 | +90% |
| 2025 | $32.5 | $30.8 | -5.4% |
| 2026 YTD | $30.8 | $64.6 | +110% |
TGTX has the edge over NVO on returns for 2026, with the stronger performance.